What UK’s Clinical Trials Overhaul Means For Orphan Drug Developers

 
• By Eliza Slawther
  
Rare disease studies could benefit from timeline extensions if they are struggling to recruit patients (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from Pathways & Standards